Sunshine Biopharma (SBFM) COO steps down immediately in leadership change

Rhea-AI Filing Summary

Sunshine Biopharma Inc. reported that on February 5, 2026, Dr. Abderrazzak Merzouki resigned from his position as chief operating officer, effective immediately. The filing does not describe any changes to other executive roles, and it is signed by Chief Executive Officer Dr. Steve N. Slilaty on behalf of the company.

false 0001402328 0001402328 2026-02-05 2026-02-05 0001402328 us-gaap:CommonStockMember 2026-02-05 2026-02-05 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2026-02-05 2026-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

SUNSHINE BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Colorado	001-41282	20-5566275
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer ID No.)

333 Las Olas Way

CU4 Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (zip code)

(954) 330-0684

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value $0.001	SBFM	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	SBFMW	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 5, 2026, Dr. Abderrazzak Merzouki resigned as chief operating officer of Sunshine Biopharma Inc., effective immediately.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 5, 2026	SUNSHINE BIOPHARMA INC.
	By: /s/ Dr. Steve N. Slilaty
	Dr. Steve N. Slilaty, Chief Executive Officer

3

FAQ

What executive change did Sunshine Biopharma (SBFM) disclose in this 8-K?

Sunshine Biopharma disclosed that Dr. Abderrazzak Merzouki resigned as chief operating officer effective February 5, 2026. The report is limited to this leadership change and does not describe any new appointments or related compensation arrangements.

When did Sunshine Biopharmas COO resignation become effective?

The resignation of Sunshine Biopharmas chief operating officer, Dr. Abderrazzak Merzouki, became effective on February 5, 2026. This date is also reported as the earliest event date for the current report on Form 8-K filed by the company.

Which executive signed Sunshine Biopharma (SBFM)s 8-K about the COO resignation?

The 8-K reporting the resignation of the chief operating officer was signed by Dr. Steve N. Slilaty, who is identified as Sunshine Biopharma Inc.s chief executive officer. His signature appears on behalf of the company as the duly authorized representative.

Does Sunshine Biopharmas 8-K describe a replacement for the departing COO?

The 8-K states that Dr. Abderrazzak Merzouki resigned as chief operating officer effective immediately but does not identify a replacement. The disclosure is focused solely on the resignation event without describing subsequent management changes or succession plans.

Under which SEC item did Sunshine Biopharma report the COO resignation?

Sunshine Biopharma reported the resignation of its chief operating officer under Item 5.02, which covers departures of directors or certain officers, elections of directors, appointments of certain officers, and compensatory arrangements of certain officers in a current report.